The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
about
Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER)Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicityAn essential difference between the flavonoids monoHER and quercetin in their interplay with the endogenous antioxidant networkOxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Doxorubicin induced heart failure: Phenotype and molecular mechanisms.A novel application of maleimide for advanced drug delivery: in vitro and in vivo evaluation of maleimide-modified pH-sensitive liposomesDexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell deathInflammatory stress and sarcomagenesis: a vicious interplay.Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review.Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats.The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB.Protective effect of bilberry (Vaccinium myrtillus) against doxorubicin-induced oxidative cardiotoxicity in rats.Activity of dexrazoxane and amifostine against late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in vivo.Investigation of therapeutic potential and molecular mechanism of vitamin P and digoxin in I/R-induced myocardial infarction in rat.
P2860
Q24336929-24ABA0B3-7DA3-44CD-800B-29E0DF8385C6Q28301317-120FCEEE-CC31-4F82-BA03-D5A263CDE6F9Q28476023-970B34CF-AC9D-45D8-B202-D8664D55C1E4Q36568908-10472C17-6554-4BD8-9D10-C5AECEF48EE4Q36912561-252DF664-259B-453C-A1B0-659135C69C9CQ37232138-19D20215-49F3-4D4E-880F-15EA0F10D69FQ37330749-553A979A-04CB-40A2-A28B-C41345341239Q37378867-4C04F74C-7EAE-4333-BD5D-2C9E5FFEB367Q38576762-957C8BBB-80FC-4011-8162-7EF3BD0822A3Q38875916-6ECA7789-0350-4A23-BD55-9965487BFEE6Q38913918-567BBCF6-B33E-43A4-9304-E0929E349DD8Q39404639-16BBF6C1-746D-4A17-9EE5-FCFD756E9FABQ39606069-49682F59-7CEE-4EA4-BF9A-A045D019638AQ41901068-87B2AFE0-100F-43F4-8430-F64A7392FCE2Q46717036-3ED342C2-0AD4-447E-9BA1-2881FDDDA8EFQ53604455-96F3A8DA-70D2-4FD8-893D-63C60A8147E6
P2860
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@ast
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@en
type
label
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@ast
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@en
prefLabel
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@ast
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@en
P2093
P2860
P356
P1476
The effect of monohydroxyethyl ...... tic cancer in a phase II study
@en
P2093
A M E Bruynzeel
C J van Groeningen
H W M Niessen
J G F Bronzwaer
J J M van der Hoeven
W J F van der Vijgh
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603994
P407
P577
2007-10-16T00:00:00Z